• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Monday, August 11, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

COVID immunity lasts up to 8 months, new data reveals

Bioengineer by Bioengineer
December 22, 2020
in Health
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Real hope for longevity of COVID vaccinations

IMAGE

Credit: Monash University

Australian researchers have revealed – for the first time – that people who have been infected with the COVID-19 virus have immune memory to protect against reinfection for at least eight months.

The research is the strongest evidence for the likelihood that vaccines against the virus, SARS-CoV-2, will work for long periods.  Previously, many studies have shown that the first wave of antibodies to coronavirus wane after the first few months, raising concerns that people may lose immunity quickly.  This new work allays these concerns.

The study is the result of a multi-centre collaboration led by Associate Professor Menno van Zelm, from the Monash University Department of Immunology and Pathology,  with the Alfred Research Alliance between Monash University, The Alfred hospital and the Burnet Institute, and published today in the prestigious journal, Science Immunology. The publication reveals the discovery that specific cells within the immune system called memory B cells, “remembers” infection by the virus, and if challenged again, through re-exposure to the virus, triggers a protective immune response through rapid production of protective antibodies.

The researchers recruited a cohort of 25 COVID-19 patients and took 36 blood samples from them from Day 4 post infection to Day 242 post infection.

As with other studies – looking only at the antibody response – the researchers found that antibodies against the virus started to drop off after 20 days post infection.

However – importantly – all patients continued to have memory B cells that recognised one of two components of the SARS-CoV-2 virus, the spike and nucleocapsid proteins. These virus-specific memory B cells were stably present as far as eight months after infection.

According to Associate Professor van Zelm, the results give hope to the efficacy of any vaccine against the virus and also explains why there have been so few examples of genuine reinfection across the millions of those who have tested positive for the virus globally.

“These results are important because they show, definitively, that patients infected with the COVID-19 virus do in fact retain immunity against the virus and the disease,” he said.

“This has been a black cloud hanging over the potential protection that could be provided by any COVID-19 vaccine and gives real hope that, once a vaccine or vaccines are developed, they will provide long-term protection.”

###

Media Contact
Tania Ewing
[email protected]

Tags: Clinical TrialsDisease in the Developing WorldMedicine/HealthPublic HealthVaccines
Share13Tweet8Share2ShareShareShare2

Related Posts

blank

Updated Guidelines on Pharmacotherapy for Obesity Management Released

August 11, 2025
blank

Neutrophil Traps Worsen Periodontitis by Disrupting T-Cells

August 11, 2025

Invasive Therapy vs. Oral Treatment: Parkinson’s Quality of Life at 12 Months

August 11, 2025

Forensic Insights: Atypical Mongolian Spots and Abuse

August 11, 2025
Please login to join discussion

POPULAR NEWS

  • blank

    Molecules in Focus: Capturing the Timeless Dance of Particles

    139 shares
    Share 56 Tweet 35
  • Neuropsychiatric Risks Linked to COVID-19 Revealed

    77 shares
    Share 31 Tweet 19
  • Modified DASH Diet Reduces Blood Sugar Levels in Adults with Type 2 Diabetes, Clinical Trial Finds

    57 shares
    Share 23 Tweet 14
  • Overlooked Dangers: Debunking Common Myths About Skin Cancer Risk in the U.S.

    61 shares
    Share 24 Tweet 15

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Updated Guidelines on Pharmacotherapy for Obesity Management Released

Neutrophil Traps Worsen Periodontitis by Disrupting T-Cells

Invasive Therapy vs. Oral Treatment: Parkinson’s Quality of Life at 12 Months

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.